American Association for Cancer Research

SHERPA: White

People

  1. Miller
    Miller
  2. Kris
    Kris
  3. Riely
    Riely
  4. Ladanyi
    Ladanyi
  5. Rusch
    Rusch
  6. Sirotnak
    Sirotnak
  7. Arcila
    Arcila
  8. Bean
    Bean
  9. Brennan
    Brennan
  10. De Stanchina
    De Stanchina

Groups

  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Advanced Practice Providers (2)
  5. Center for Hematologic Malignancies (2)
  6. GSK Faculty (2)
  7. Gastrointestinal Oncology Service (2)
  8. Hematologic Malignancies, Division of (2)
  9. Human Oncology and Pathogenesis Program (2)
  10. Lymphoma (2)
Search Within
  1. "Vincent Miller"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (2)
Groups
  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Advanced Practice Providers (2)
  5. Center for Hematologic Malignancies (2)
  6. GSK Faculty (2)

More Groups

People
  1. Vincent Miller (14)
  2. Mark Kris (9)
  3. Raymond Warrell (5)
  4. James Rigas (4)
  5. William Tong (4)
  6. Gregory Riely (3)

More People

Years
  1. 2014 (1)
  2. 2012 (1)
  3. 2007 (4)
  4. 2002 (1)
  5. 2000 (1)
  6. 1999 (1)

More Years

Publications
  1. Proceedings of the American Association for Cancer Research Annual Meeting (8)
  2. Molecular Cancer Therapeutics (4)
  3. Cancer Discovery (2)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
    Journal Article

    Janjigian, Y. Y.; Smit, E. F.; Groen, H. J. M.; Horn, L.; Gettinger, S.; Camidge, D. R.; Riely, G. J.; Wang, B.; Fu, Y.; Chand, V. K.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation
    Journal Article

    Takezawa, K.; Pirazzoli, V.; Arcila, M. E.; Nebhan, C. A.; Song, X.; de Stanchina, E.; Ohashi, K.; Janjigian, Y. Y.; Spitzler, P. J.; Melnick, M. A.; more...
    Cancer Discovery (2012)

    Fulltext@MSK | Save
  • A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations
    Meeting Abstract

    Rizvi, N.; Kris, M.; Miller, V.; Krug, L.; Bekele, S.; Dowlati, A.; Rowland, K.; Tonda, M.; Mitchell, B.; Ruckdeschels, J.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    James, L. P.; Azzoli, C. G.; Krug, L. M.; Miller, V.; Tripathi, P.; Subzwari, S.; Tyson, L. B.; Dunne, M.; Huntington, M. F.; Saunders, M. E.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • A pilot phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung
    Meeting Abstract

    Haura, E. B.; Larson, T. G.; Stella, P. J.; Bazhenova, L.; Miller, V. A.; Cohen, R. B.; Eisenberg, P. D.; Selaru, P.; Wilner, K. D.; Ricart, A. D.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    Meeting Abstract

    Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • The selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') enhances radiation sensitivity of human tumor xenografts in nude mice
    Meeting Abstract

    She, Y.; Lee, F.; Haimovitz-Friedman, A.; Miller, V. A.; Rusch, V. W.; Kris, M. G.; Sirotnak, F. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (IressaTM), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
    Meeting Abstract

    Sirotnak, F. M.; Zakowski, M. F.; Miller, V. A.; Scher, H. I.; Kris, M. G.
    Proceedings of the American Association for Cancer Research Annual Meeting (2000)

    Fulltext@MSK | Save
  • Phase II trial of docetaxel and vinorelbine in advanced non-small cell lung cancer (NSCLS) with analysis of bcl-2 and bax expression
    Meeting Abstract

    Krug, L. M.; Filippa, D. A.; Kris, M. G.; Zelenetz, A.; Heelan, R. T.; Grant, S. C.; Ng, K. K.; Pizzo, B. A.; Miller, V. A.
    Proceedings of the American Association for Cancer Research Annual Meeting (1999)

    Fulltext@MSK | Save
  • Chemoprevention of respiratory tract cancers
    Meeting Abstract

    Brooks, A. D.; Benedetti, F.; Tong, W. P.; Miller, V. A.; Burt, M.; Kris, M. G.; Warrell, R. P.
    Proceedings of the American Association for Cancer Research Annual Meeting (1997)

    Fulltext@MSK | Save